RedHill Biopharma Issued Key US Patents for Promising Crohn’s Disease Treatment Candidate

RedHill Biopharma Issued Key US Patents for Promising Crohn’s Disease Treatment Candidate
Israel-based biopharmaceutical company RedHill Biopharma Ltd. recently announced its acquisition of two notices of allowance from the United States Patent and Trademark Office (USPTO) covering patient application numbers 13/722,395 and 14/271,758 for RHB-104, a novel antibiotic combination treatment in oral capsule form. The drug boasts an improved formulation that features enhanced intracellular, anti-mycobacterial and anti-inflammatory properties. At present, it is undergoing its first Phase III study as a potential treatment for Crohn's disease, and a Phase IIa study for multiple sclerosis. RedHill is expecting patent application number 13/722,395, titled, "Methods and Compositions for Treating Inflammatory Bowel Disease," to be valid until October 2029, and patent application number 14/271,758 titled "Methods and Compositions Comprising Rifabutin, Clarithromycin, and Clofazamine," to be valid until at least February 2029. The company's Director of Intellectual Property & Research, Danielle Abramson, PhD, said: "Once issued, these two new U.S. patents, carrying a patent term through at least 2029, will further enhance RedHill's global patent portfolio covering RHB-104, a potential groundbreaking treatment for Crohn's disease." The drug's ongoing pioneering Phase III study testing RHB-104 as a possible novel treatment for Crohn's disease is a randomized, double-blind, placebo-controlled MAP US Phase III study that aims to enlist the participation of 270 patients with a moderately to severely active form of the disease. The test subjects are randomized 1
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *